Rank |
Status |
Study |
1 |
Recruiting
|
Bioavailability of Potassium From Potatoes and Potassium Gluconate
Conditions: |
Potassium Bioavailability; Blood Pressure |
Interventions: |
Dietary Supplement: Placebo control; Dietary Supplement: Low dose Potassium gluconate; Dietary Supplement: Medium dose Potassium gluconate; Dietary Supplement: High dose Potassium gluconate; Dietary Supplement: Low dose potato; Dietary Supplement: Medium dose potato; Dietary Supplement: High dose potato; Dietary Supplement: High dose French fries; Dietary Supplement: Basal diet control |
Outcome Measures: |
Bioavailability of Potassium; Blood Pressure Response to Potassium |
|
2 |
Not yet recruiting
|
Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
Condition: |
Hyperkalemia |
Intervention: |
Behavioral: decision support in Potassium-inc. drug-drug-interactions |
Outcome Measures: |
Impact on serum Potassium monitoring during Potassium-increasing drug-drug-interactions; Frequency of hyperkalemia during Potassium-increasing drug-drug-interactions; Frequency of Potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia; Frequency of transfers to the ICU during Potassium-increasing drug-drug-interactions in function of the serum Potassium level; Frequency of death during Potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia; Change in frequency distribution of serum Potassium monitoring intervals; Response of physicians to the computer-based alerts and reminders |
|
3 |
Recruiting
|
Comparison of Enteral Versus Intravenous Potassium Supplementation
Condition: |
Acute Hypokalemia |
Interventions: |
Drug: Intravenous Potassium chloride; Drug: Oral Potassium chloride |
Outcome Measures: |
The efficacy EPR and IVPR for treatment of hypokalemia (measured as change in serum Potassium levels in milliequivalent/liter (mEq/L) after Potassium replacement; Comparison of adverse effects after EPR and IVPR.; Comparison of number of dose/s required to achieve resolution of hypokalemia; Efficacy of EPR and IVPR for various degrees of severity of hypokalemia for each episode of hypokalemia |
|
4 |
Unknown †
|
Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients
Condition: |
Condition Requiring Rapid Transfusion During Liver Transplantation Surgery |
Intervention: |
|
Outcome Measures: |
Potassium concentration in the Fluid Management System (FMS) reservoir; plasma Potassium of the patient |
|
5 |
Not yet recruiting
|
Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
Condition: |
Nephrocalcinosis |
Interventions: |
Drug: Potassium Citrate; Drug: Placebo |
Outcome Measures: |
incidence of nephrocalcinosis in extremely preterm infants; Determine whether the administration of Potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks; To determine whether administration of Potassium citrate improves the levels of urinary phosphorus, Potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value; Determine whether the administration of Potassium citrate improves the plasma levels of sodium, Potassium, creatinine, calcium, and ph value.; To determine the incidence of adverse events and serious adverse events related to study treatment. |
|
6 |
Unknown †
|
Effects of Potassium Salts on Blood Pressure and Target Organ Damage
Condition: |
Hypertension |
Intervention: |
Behavioral: Potassium supplementation |
Outcome Measures: |
Blood pressure and markers of target organ damage and bone health at 4 weeks of Potassium supplementation.; Comparisons among different treatments in blood pressure and markers of target organ damage and bone health. |
|
7 |
Recruiting
|
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Condition: |
Hypertension |
Interventions: |
Drug: Potassium chloride powder; Drug: Potassium citrate powder; Drug: Potassium magnesium citrate powder; Drug: Placebo |
Outcome Measures: |
24-hour blood pressure; Office blood pressure; Serum C-terminal telopeptide (CTX); 24-hour urinary calcium; Carotid to femoral pulse wave velocity; Central aortic blood pressure |
|
8 |
Recruiting
|
Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
Conditions: |
Atrial Fibrillation; Atrial Flutter; Potassium; Cardioversion |
Intervention: |
Drug: Potassium chloride |
Outcome Measures: |
Cardioversion (time and percentage); Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period. |
|
9 |
Recruiting
|
Combined Dietary Education of Low Sodium and High Potassium Consumption
Conditions: |
Prehypertension; Hypertension |
Interventions: |
Behavioral: dietary education of low sodium and high Potassium consumption; Behavioral: dietary education of low sodium consumption only |
Outcome Measures: |
changes of 24-hour ambulatory systolic and diastolic blood pressure; changes of 24-hour urine sodium and Potassium excretion; changes of renin and aldosterone |
|
10 |
Not yet recruiting
|
Investigating a New Way of Giving Medicine to Newborn and Preterm Babies
Conditions: |
Hypophosphataemia; Osteopenia of Prematurity |
Interventions: |
Drug: Oral thin film therapy (Potassium acid phosphate oral thin films); Drug: Standard therapy (Potassium acid phosphate oral solution) |
Outcome Measures: |
Serum phosphate; Age-appropriateness |
|
11 |
Unknown †
|
Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone
Condition: |
Acute Coronary Syndrome |
Interventions: |
Drug: glucose insulin Potassium; Drug: GIK and intensive insulin therapy |
Outcome Measures: |
30 days mortality, reinfarction, urgent coronary revascularisation, and stroke.; Severe dysrhythmias, acute left ventricular failure with ejection fraction<45%, change of serum B-type natriuretic peptide (BNP), serum troponin, and platelet factor activator (PFA-100) within 24 hours after the start of protocol treatment. |
|
12 |
Recruiting
|
Potassium Citrate Supplementation vs. Dietary Counseling
Condition: |
Kidney Stone |
Interventions: |
Dietary Supplement: Potassium Citrate Supplementation; Other: Dietary Education |
Outcome Measure: |
Change in 24-hour urine parameters |
|
13 |
Recruiting
|
Musculoskeletal Effects of Bicarbonate
Conditions: |
Age-related Bone Loss; Age Related Muscle Loss; Falls; Fractures |
Interventions: |
Dietary Supplement: Potassium bicarbonate; Other: placebo |
Outcome Measures: |
The primary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary N-telopeptide/creatinine ratio; The secondary aim is to identify the dose of KHCO3 needed for maximal suppression of 24-hr urinary nitrogen/creatinine ratio |
|
14 |
Recruiting
|
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Condition: |
Gastric Cancer |
Interventions: |
Drug: Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin; Drug: Oxaliplatin; Capecitabine |
Outcome Measures: |
Disease-free survival(DFS); Objective response rate (ORR); Disease control rate (DCR); Down staging rate; Overall survival (OS); Adverse events; R0-resection rate |
|
15 |
Unknown †
|
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
Condition: |
Molluscum Contagiosum |
Interventions: |
Drug: Hydroxide Potassium; Drug: Placebo |
Outcome Measure: |
Efficacy (diseappearance of lesions) |
|
16 |
Unknown †
|
The Effects of Potassium Citrate on Bone Metabolism
Conditions: |
Bone Diseases, Metabolic; Osteoporosis, Postmenopausal |
Intervention: |
Drug: Potassium citrate |
Outcome Measures: |
Bone turnover markers; Bone Density by DEXA |
|
17 |
Recruiting
|
Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity
Condition: |
Dentin Sensitivity |
Intervention: |
Device: Potassium oxalate |
Outcome Measure: |
Dentin sensitivity |
|
18 |
Recruiting
|
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
Conditions: |
Glomerulonephritis; Proteinuria |
Interventions: |
Drug: Shenyankangfu tablets; Drug: Losartan Potassium 50mg; Drug: Shenyankangfu tablets and Losartan Potassium 50mg; Drug: Shenyankangfu tablets and Losartan Potassium 100mg; Drug: Losartan Potassium 100mg |
Outcome Measures: |
changes of 24 hours proteinuria after the treatment; changes of serum creatinine after treatment; changes of eGFR after the treatment; changes of Traditional Chinese Medicine syndrome scores after the treatment |
|
19 |
Recruiting
|
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
Condition: |
Cough |
Interventions: |
Drug: Syrup of oxomemazine, guaifenesin and Potassium iodate; Drug: Syrup of guaifenesin |
Outcome Measures: |
Reduction/improvement of cough symptoms; Tolerance |
|
20 |
Unknown †
|
Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns
Condition: |
Healthy Infants |
Intervention: |
|
Outcome Measure: |
Potassium Measurements |
|